Fifty-six Acinetobacter species strains (49 Acinetobacter baumanii, 5 Acinetobacter calcoaceticus, 2 Acinetobacter iwoffii) were detected using both conventional methods and gas chromatography of bacterial fatty acids with the MIDI Sherlock® Microbial Identification System. The susceptibilities of these strains to 16 antimicrobial agents were investigated by the disc-diffusion method according to the National Committee for Clinical Laboratory Standards. The production of extended-spectrum β-lactamases (ESBLs) and inducible β-lactamases (IBLs) by the strains were investigated by the double-discsynergy and disc-approximation methods, respectively. Imipenem was the most effective agent for Acinetobacter baumanii strains (95.9% of strains were sensitive), while meropenem and netilmicin showed moderate activity (87.7% and 79.6% of strains, respectively, responded). Acinetobacter baumanii strains were less sensitive to cefoperazone-sulbactam (53.1%), ofloxacin (51.0%), ciprofloxacin (42.8%), and amikacin (36.7%). Acinetobacter calcoaceticus and Acinetobacter iwoffii strains were sensitive to imipenem, meropenem and netilmicin. IBLs and ESBLs were produced, respectively, by 8.9% and 7.1% of all bacterial strains. The strains isolated were sufficiently sensitive to imipenem, but not to ofloxacin or ciprofloxacin, and were very resistant to amikacin.
BernardsATvan der ToomJvan BovenCPDijkshoomL: Evaluation of the ability of a commercial system to identify Acinetobacter genomic species. Eur J Clin Microbiol Infect Dis1996; 15: 303–308.
BoukadidaJ: Ecological aspects and prophylaxis of Acinetobacter baumanii nosocomial infection. Tunis Med2000; 78: 480–483.
4.
SuriAMahapatraAKKapilA: Acinetobacter infection in neurosurgical intensive care patients. Natl Med J India2000; 13: 296–300.
5.
TownerKJ: Clinical importance and antibiotic resistance of Acinetobacter spp. Proceedings of a symposium held on 4–5 November 1996 at Eilat, Israel. J Med Microbiol1997; 46: 721–746.
6.
HumphreysHTownerKJ: Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland. J Hosp Infect1997; 37: 281–286.
7.
Bergogne-BerezinE: The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect1995; 30 (Suppl): 441–452.
8.
SaderHSJonesRNAndrade-BaiocchiSBiedenbachDJ: Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn Microbiol Infect Dis2002; 44: 273–280.
9.
GunserenFMamikogluLOzturkSYucesoyMBiberogluKYulugN: A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother1999; 43: 373–378.
10.
KonemanEWAllenSDJandaWMSchreckenbergerPCWinnWCJr: Color Atlas and Textbook of Diagnostic Microbiology, 5th edn.Philadelphia: Lippincott, 1997; pp 292–306.
11.
Bergogne-BerezinEJoly-GuillouMLTownerKJ: History and importance of Acinetobacter spp., role in infections, treatment and cost implications. In: Acinetobacter (Bergogne-BerezinEJoly-GuillouMLTownerKJ, eds). New York, NY, USA: CRC Press, Inc., 1996; pp2–13.
12.
National Committee for Clinical Laboratory Standards 1999: Performance standards for antimicrobial susceptibility testing. Ninth informational supplement, M100–S9. Pennsylvania, USA: NCCLS1999.
13.
GencerSAkOBenzonanaNBatirelAOzerS: Susceptibility patterns and cross resistances of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob2002, 1: 2–5.
14.
BongaertsGRoelofs-WillemseH: In vitro expression of beta-lactam-induced response by clinical gram-negative bacteria with the potential for inducible beta-lactamase production. Scand J Infect Dis1998; 30: 579–583.
15.
McDonaldLCWalkerMCarsonLArduinoMAgueroSMGomezPMcNeilPJarvisWR: Outbreak of Acinetobacter spp. bloodstream infections in a nursery associated with contaminated aerosols and air conditioners. Pediatr Infect Dis J1998; 17: 716–722.
16.
GomezJSimarroEBanosVRequenaLRuizJGarciaF: Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumanii. Eur J Clin Microbiol Infect Dis1999; 18: 358–361.
17.
GalesACSaderHHJonesRN: Respiratory pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997–2000). Diagn Microbiol Infect Dis2002; 44: 301–311.
18.
BayugaSZeanaCSahniJDella-LattaPel SadrWLarsonE: Prevalence and antimicrobial patterns of Acinetobacter baumanii on hands and nares of hospital personnel and patients: the iceberg phenomenon again. Heart Lung2002; 31: 382–390.
MusaEKDesaiNCasewellMW: The survival of Acinetobacter calcoaceticus inoculated on fingertips and formica. J Hosp Infect1990; 15: 219–227.
21.
Getchell-WhiteSIDonowitzLGGroschelDHM: The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acinetobacter calcoaceticus. Infect Control Hosp Epidemiol1989; 10: 402–406.
22.
AygünGDemirkiranOUtkuTMeteBÜrkmezSYilmazM: Environmental contamination during a carbapenem-resistant Acinetobacter baumanii outbreak in an intensive care unit. J Hosp Infect2002; 52: 259–262.
23.
SinghNYuVL: Rational empiric antibiotic prescription in the ICU: Clinical research is mandatory. Chest2000; 117: 1496–1499.
24.
Joly-GuillouMLBrun-BuissonC: Epidemiology of Acinetobacter spp.: surveillance and management of outbreaks. In: Acinetobacter (Bergogne-BerezinEJoly-GuillouMLTownerKJ, eds). New York, NY, USA: CRC Press, Inc., 1996; pp71–101.
25.
Bergogne-BerezinE: Resistance of Acinetobacter spp. to antimicrobials — overview of clinical resistance patterns and therapeutic problems. In: Acinetobacter (Bergogne-BerezinEJoly-GuillouMLTownerKJ, eds). New York, NY, USA: CRC Press, Inc., 1996; pp133–185.
SaderHSJonesRNSilvaJB: Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis2002; 44: 281–288.
28.
LambertTGerbaudGBouvetPVieuJFCourvalinP: Dissemination of amikacin resistance gene aphA6 in Acinetobacter spp. Antimicrob Agents Chemother1990; 34: 1244–1248.
29.
AmyesSGBYoungHK: Mechanisms of antibiotic resistance in Acinetobacter spp.—genetics of resistance. In: Acinetobacter (Bergogne-BerezinEJoly-GuillouMLTownerKJ, eds). New York, NY, USA: CRC Press, Inc., 1996; pp185–225.
30.
BrooksSEWalczacMAHameedR: Are we doing enough to contain Acinetobacter infections?Infect Control Hosp Epidemiol2000; 21: 304.
31.
Centers for Disease Control and Prevention Healthcare Infection Control Practices Advisory Committee (HICPAC).Draft Guideline for Environmental Infection Control in Healthcare Facilities, 2001; 7–56.
32.
Guidelines for Hand Hygiene in Health-care Settings.Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. MMWR2002; 51: 1–44.
